



## UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

May 2, 2019

*Conference Call and Webcast Scheduled for 8:30 AM ET*

NEW YORK--(BUSINESS WIRE)--May 2, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30AM Eastern Time.

### **Audio Webcast**

The webcast will be made available on the Investors section of the Company's website at <http://investors.urogen.com>. Following the live audio webcast, a replay will be available on the Company's website for approximately two weeks.

### **Dial-In Information**

Live (U.S. / Canada): 1 (888) 771-4371  
Live (International): 1 (847) 585-4405  
Confirmation number: 48486174

### **About UroGen Pharma Ltd.**

UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190502005133/en/>

Source: UroGen Pharma Ltd.

### **UROGEN CONTACT:**

Kate Bechtold  
Director, Corporate Communications & Investor Relations  
[Kate.Bechtold@urogen.com](mailto:Kate.Bechtold@urogen.com)  
914-552-0456